SRR12202422
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.540
- G2M_CHECKPOINT+0.390
- INTERFERON_ALPHA_RESPONSE+0.370
- DNA_REPAIR+0.340
- OXIDATIVE_PHOSPHORYLATION+0.310
- SPERMATOGENESIS+0.280
- INTERFERON_GAMMA_RESPONSE+0.240
- MITOTIC_SPINDLE+0.220
- PROTEIN_SECRETION+0.200
- FATTY_ACID_METABOLISM+0.180
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.600
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.520
- ANGIOGENESIS-0.480
- HEDGEHOG_SIGNALING-0.450
- MYOGENESIS-0.440
- NOTCH_SIGNALING-0.420
- HYPOXIA-0.400
- APICAL_JUNCTION-0.350
- TGF_BETA_SIGNALING-0.350
- P53_PATHWAY-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12202426 | — | — | 0.879 |
| 2 | c94686d5.355c.432f.bc98.ccdd30a209de | — | cohortA4 | 0.877 |
| 3 | TCGA-BB-A6UM-01A-12R-A34R-07 | — | — | 0.868 |
| 4 | TCGA-A8-A081-01A-11R-A00Z-07 | — | C | 0.853 |
| 5 | GSM6454730 | — | D | 0.843 |
| 6 | SRR8942940 | — | — | 0.841 |
| 7 | R137 | — | — | 0.841 |
| 8 | C3L-01000 | — | cohortA4 | 0.840 |
| 9 | SRR23303773 | — | — | 0.833 |
| 10 | TCGA-CR-7385-01A-11R-2016-07 | — | — | 0.831 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.540 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.390 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.370 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.340 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.310 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.280 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.240 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.220 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.110 | Idelalisib | — uncovered |
| PEROXISOME | 0.110 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| COMPLEMENT | 0.020 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.020 | Inavolisib | — uncovered |